Results 281 to 290 of about 257,746 (309)

Antigen presentation to CD8+ T cells

Current opinion in immunology, 2001
Recent studies indicate that, in most types of infections, antigen presentation by 'professional' bone-marrow-derived cells is essential for priming pathogen-specific CD8+ T cells. This is true even in the absence of direct infection of these cells, which indicates that cross-priming is an essential component of the immune response against pathogens.
den Haan, J M, Bevan, M J
openaire   +1 more source

Soluble CD8 antigen in systemic sclerosis.

Journal of clinical & laboratory immunology, 1990
In 15 patients suffering from systemic sclerosis (PSS) the function of CD8+ circulating lymphocytes was assayed by determining soluble CD8 antigen (sCD8) both in sera and in 48 hr PHA-conditioned media of peripheral blood mononuclear cells (PBMCs). Furthermore, the frequency of circulating activated CD8+ cells, which express DR antigens, interleukin-2 ...
Famularo G, GIACOMELLI, Roberto, Sacchetti S, Danese C, Luciani AM, Perego MA, Tonietti G.   +6 more
openaire   +2 more sources

Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection

Clinical Immunology and Immunopathology, 1992
Increases in plasma levels of soluble CD8 (SCD8) antigen and expansion of the CD8+ CD38+ lymphocyte compartment were early immunologic alterations frequently observed prior to detection of antibodies against human immunodeficiency virus type 1 (HIV-1) and diminution of CD4+ cells in subjects at risk to develop AIDS. These increases identified in the 49
M J, Yagi, F N, Chu, J D, Jiang, J, Wallace, P, Mason, Y, Liu, J, Carafa, J G, Bekesi   +7 more
openaire   +2 more sources

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

Experimental Hematology, 2007
Preclinical and clinical trials are investigating the potential of T cells genetically modified to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas.
Tontanai, Numbenjapon, Lisa M, Serrano, Wen-Chung, Chang, Stephen J, Forman, Michael C, Jensen, Laurence J N, Cooper   +5 more
openaire   +2 more sources

Human melanoma antigens recognized by CD8+ T cells

2003
Summary Melanoma is a relatively immunogenic cancer and responds to various immunotherapies. Clinical and immunological observations obtained from patients received various immunotherapy protocols indicate that CD8 T cells are involved in in vivo tumor rejection, and melanoma reactive CD8 T cells with various antigen specificity were generated from the
openaire   +2 more sources

Soluble CD8 Antigen in Plasmodium falciparum Malaria

Journal of Infectious Diseases, 1989
P G, Kremsner, U, Bienzle
openaire   +2 more sources

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Nature, 2021
Giacomo Oliveira, Susan Klaeger, Dennie T Frederick   +2 more
exaly  

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

Nature Reviews Cancer, 2021
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre   +2 more
exaly  

Assessing antigen-specific CD8+ CTL responses in humans.

Methods in molecular medicine, 2002
Townsend and colleagues (1) were the first to demonstrate, in 1984, that target cells that had been transfected with single viral RNA segments could be specifically recognized by cytotoxic T lymphocytes (CTL). Recombinant vaccinia viruses that expressed single-gene products were subsequently used to identify major target antigens for CTL (2,3).
openaire   +2 more sources

The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck

Cell, 1988
André Veillette
exaly